IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-23 (canceled)

- 24. (previously presented) A viral vector comprising an Simian Immunodeficiency Virus (SIV) packaging signal and a heterologous gene capable of being expressed in the vector, wherein the SIV packaging signal comprises the sequence of SEQ ID NO:1.
- 25. (currently amended) A vector according to claim 24 further comprising <u>a sequence</u> the region between the <u>SIV</u> 5' major splice donor site and the <u>SIV</u> gag initiation codon or a fragment of either thereof.
- 26. (previously presented) A viral vector comprising an Simian Immunodeficiency Virus (SIV) packaging signal and a heterologous gene capable of being expressed in the vector, wherein the SIV packaging signal comprises nucleotides 53-85 of SEQ ID NO:1.
- 27. (currently amended) A vector according to claim 26 further comprising <u>a sequence</u> the region between the <u>SIV</u> 5' major splice donor site and the <u>SIV</u> gag initiation codon or a fragment of either thereof.
- 28. (previously presented) A vector according to claim 24, wherein the heterologous gene encodes a therapeutic protein or peptide, or an antigenic protein or peptide.
- 29. (previously presented) A vector according to claim 26, wherein the heterologous gene encodes a therapeutic protein or peptide, or an antigenic protein or peptide.
- 30. (previously presented) A process for producing a virus encoding a heterologous gene, which process comprises infecting a host cell with a packaging defective Simian Immunodeficiency Virus (SIV) genome having a mutation in the packaging signal such

that the viral RNA is not packaged within an SIV capsid and a viral vector comprising an SIV packaging signal and a heterologous gene capable of being expressed in the vector according to claim 24, and culturing the infected host cell.

- 31. (previously presented) A process according to claim 30 further comprising formulating the virus as a composition with a carrier or diluent.
- 32. (previously presented) A virus produced by the process of claim 30.
- 33. (previously presented) A composition comprising the virus according to claim 32 and a carrier or diluent.
- 34. (previously presented) A process for producing a virus encoding a heterologous gene, which process comprises infecting a host cell with a packaging defective Simian Immunodeficiency Virus (SIV) genome having a mutation in the packaging signal such that the viral RNA is not packaged within an SIV capsid and a viral vector comprising an SIV packaging signal and a heterologous gene capable of being expressed in the vector according to claim 26, and culturing the infected host cell.
- 35. (previously presented) A process according to claim 34 further comprising formulating the virus as a composition with a carrier or diluent.
- 36. (previously presented) A virus produced by the process of claim 34.
- 37. (previously presented) A composition comprising the virus according to claim 36 and a carrier or diluent.
- 38. (new) A vector according to claim 24 further comprising the sequence from 985 to 1054 as shown in Fig. 1a.

LEVER et al. - Appln. No. 10/009,171

39. (new) A vector according to claim 24 further comprising the sequence of SEQ ID NO:2 or a fragment thereof.

40. (new) A vector according to claim 26 further comprising the sequence from 985 to 1054 as shown in Fig. 1a.

41. (new) A vector according to claim 26 further comprising the sequence of SEQ ID NO:2 or a fragment thereof.